Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Return on Sales (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Return on Sales for 10 consecutive years, with 129.67% as the latest value for Q4 2025.

  • Quarterly Return on Sales changed N/A to 129.67% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 129.67% through Dec 2025, changed N/A year-over-year, with the annual reading at 14.2% for FY2025, N/A changed from the prior year.
  • Return on Sales for Q4 2025 was 129.67% at Crescent Biopharma, up from 47.88% in the prior quarter.
  • The five-year high for Return on Sales was 129.67% in Q4 2025, with the low at 101403.25% in Q2 2021.
  • Average Return on Sales over 4 years is 8747.12%, with a median of 382.75% recorded in 2021.
  • The sharpest move saw Return on Sales crashed -10139901bps in 2021, then soared 10122635bps in 2022.
  • Over 4 years, Return on Sales stood at 988.47% in 2021, then skyrocketed by 37bps to 622.52% in 2022, then rose by 9bps to 565.27% in 2023, then surged by 123bps to 129.67% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 129.67%, 47.88%, and 20.31% for Q4 2025, Q3 2025, and Q2 2025 respectively.